Natural Killer (NK) Cell Therapeutics Market Report 2026

The natural killer (nk) cell therapeutics market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to limitations of traditional cancer therapies, advancements in immunology research, success of early nk cell therapies, growth of cell therapy infrastructure, increased oncology research funding.

The natural killer (nk) cell therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.9 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expansion of cell and gene therapy pipelines, increasing demand for safer immunotherapies, advancements in cell engineering technologies, rising investment in oncology biologics, growing acceptance of allogeneic cell therapies. Major trends in the forecast period include rapid development of car-nk cell therapies, increasing use of allogeneic nk cell treatments, growing focus on off-the-shelf cell therapies, expansion of nk cell applications in oncology, rising clinical trials for nk-directed antibodies.

The rising prevalence of cancer is expected to drive the growth of the natural killer (NK) cell therapeutics market going forward. Cancer encompasses diseases in which abnormal cells grow uncontrollably, invade nearby tissues, and spread to other parts of the body. This disrupts normal cell regulation, leads to tumor formation, and impairs bodily functions. Environmental exposures, such as pollutants, tobacco smoke, and chemicals, can damage DNA and disrupt cellular processes, increasing cancer risk. Natural killer (NK) cell therapeutics aid in cancer treatment by directly targeting and destroying tumor cells without prior sensitization. For instance, in April 2024, according to the American Cancer Society, a US-based non-profit organization, cancer cases are projected to reach 35 million by 2050 based solely on population growth. Therefore, the rising prevalence of cancer is fueling the expansion of the NK cell therapeutics market.

Major companies in the natural killer (NK) cell therapeutics market are focusing on innovations such as scalable iPSC-based NK cell manufacturing platforms to provide cost-effective, off-the-shelf NK cell therapies. These platforms leverage induced pluripotent stem cells (iPSCs) to produce NK cells in a standardized, feeder-free, closed-system bioreactor, ensuring high yields and compliance with regulatory standards. For instance, in April 2025, Cellistic, a Belgium-based biotechnology company, launched the Echo-NK platform, an iPSC-based manufacturing solution for NK cell therapies. This platform enables scalable production of NK cells targeting blood cancers, solid tumors, and autoimmune diseases, with all key expansion steps conducted in bioreactor closed systems within Cellistic's EMA-certified GMP facility. By combining Cellistic's Pulse cell line development capabilities with proprietary STAR-CRISPR technology, the Echo-NK platform accelerates the creation of stable iPSC lines with specific gene edits, offering a commercially viable route for off-the-shelf NK cell therapies.

In March 2025, AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, acquired EsoBiotec for up to $1 billion, comprising an initial payment of $425 million and up to $575 million in milestone-based contingent payments. Through this acquisition, AstraZeneca aims to leverage EsoBiotec’s platform to make cell therapies more accessible, scalable, and cost-effective for cancer patients worldwide, significantly expanding its cell therapy portfolio. EsoBiotec is a Belgium-based biotechnology company specializing in cell therapeutics development.

Major companies operating in the natural killer (nk) cell therapeutics market are Sanofi S.A., Thermo Fisher Scientific, Lonza AG, Catalent, Kite Pharma, Fate Therapeutics, Artiva Biotherapeutics, Nkarta Inc, Celularity Inc., NKGen Biotech, Dragonfly Therapeutics, Cytovia Therapeutics, Glycostem Therapeutics, Gamida Cell, ONK Therapeutics, Wugen Inc., AGC Biologics, CytoImmune Therapeutics, XNK Therapeutics, Indapta Therapeutics, Neukio Biotherapeutics, Senti Biosciences, WuXi Advanced Therapies, Kiadis Pharma.

North America was the largest region in the natural killer (NK) cell therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the natural killer (nk) cell therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the natural killer (nk) cell therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the natural killer cell therapeutics market by increasing costs of imported cell processing equipment, biologic reagents, and cryopreservation materials. These impacts are most evident in car-nk cell therapies and advanced clinical trial programs, particularly across North America, Europe, and Asia-Pacific. Higher tariffs have increased development and treatment costs for hospitals and research institutes. Positively, tariffs have supported domestic cell therapy manufacturing and regional innovation ecosystems.

The natural killer (nk) cell therapeutics market research report is one of a series of new reports that provides natural killer (nk) cell therapeutics market statistics, including natural killer (nk) cell therapeutics industry global market size, regional shares, competitors with a natural killer (nk) cell therapeutics market share, detailed natural killer (nk) cell therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the natural killer (nk) cell therapeutics industry. This natural killer (nk) cell therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Natural Killer (NK) cell therapeutics are treatments that utilize or enhance NK cells, a type of immune cell, to identify and destroy cancerous, infected, or otherwise diseased cells. These therapies include NK cell infusions (autologous or allogeneic), CAR-NK cells (genetically engineered to target specific proteins), and NK-directed antibodies (including bispecific antibodies).

The primary therapeutics in the NK cell space are NK cell-directed antibodies and NK cell-based therapies. NK cell-directed antibodies are designed to enhance NK cells’ ability to detect and eliminate cancer cells by targeting tumor-specific antigens. These therapies are applied in areas such as cancer, immunoproliferative disorders, gastrointestinal diseases, and more. Distribution channels include hospital pharmacies, direct tenders, and others, with end-users primarily consisting of hospitals, specialty clinics, and research or academic institutions.

The natural killer (NK) cell therapeutics market includes revenues earned by entities by providing services such as scell therapy development, clinical trial support, contract manufacturing, regulatory consulting, and cell line engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The natural killer (NK) cell therapeutics market also includessales of cytokine-activated NK cells, CAR-NK cell therapies, cell expansion kits, reagents, and culture media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.